Page 2 - Sun Pharmaceutical Industries Ltd News

Q3 results: Sun Pharma, GAIL, IDFC first bank, Delhivery, 72 more on Jan 31

Q3FY26 company results: Firms including Bharat Dynamics, ZF Steering Gear India, R R Kabel, Finolex Industries and Reliance Infrastructure are also to release their October-December earnings today

These are most overbought, oversold stocks on BSE, NSE ahead of Budget 2026

A technical scan on Nifty 500 stocks reveals that 6 shares were trading in overbought territory based on the RSI parameter, while 66 languished in the oversold zone a day ahead of the Union Budget.

Sun Pharma Q3 Preview: Profit, revenue and key factors to watch in Dec qtr

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

China halts import, sale of Sun Pharma's Alzheimer's drug after inspection

In 2024, the ​USFDA issued a warning letter to Sun Pharma alleging 'significant violations' of 'current good manufacturing practice' ‍regulations for pharma made at the same production site in India

Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA

Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug Administration. As per its latest Enforcement Report, the US-based arm of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication to treat dandruff and skin conditions with inflammation and itching. The Princeton (New Jersey)-based Sun Pharmaceutical Industries Inc is recalling 24,624 bottles of Fluocinolone Acetonide Solution Topical Solution for "Failed Impurities/Degradation Specifications", the US health regulator said. The company initiated the Class III nationwide (US) recall on December 30, 2025. The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris. Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results f

Sun Pharma terms $10 billion Organon acquisition reports 'speculative'

Sun Pharmaceutical said reports of a $10 billion acquisition of US-based Organon are speculative, adding there is no material information requiring disclosure to exchanges

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

The USFDA said the affected batch of Taro shampoos failed to meet impurity or degradation specifications

Sun Pharma shares slip 3% after US FDA flags Baska manufacturing facility

Sun Pharma's Baska plant in Gujarat receives OAI status from the US FDA after inspection, adding near-term regulatory uncertainty but not impacting current US supplies

Sun Pharma shares fall over 2% after USFDA flags facility as OAI

The USFDA conducted an inspection at the company's Baska facility from 8 September 2025 to 19 September 2025 and has subsequently classified the inspection outcome as Official Action Indicated (OAI)

Delhi HC allows Sun Pharma to export semaglutide, restricts sale in India

The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk holds no patent, but barred sales in India until March 2026

Delhi HC allows Sun Pharma to manufacture, export its weight loss drug

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

Sun Pharma unit to invest ₹3,000 cr for new plant in Madhya Pradesh

A unit of Sun Pharmaceutical Industries plans to invest Rs 3,000 crore on a new manufacturing plant in Madhya Pradesh, according to a regulatory filing. The board of Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has approved the proposal for setting up a greenfield formulations manufacturing facility in the state, the Mumbai-based drug major said in a filing on Tuesday. Shares of Sun Pharma on Wednesday ended 0.43 per cent higher at Rs 1,805.70 apiece on BSE.

Sun Pharma launches blockbuster plaque psoriasis drug Ilumya in India

Ilumya, a novel biologic treatment that selectively inhibits IL-23, has already established itself as a blockbuster drug internationally, with presence across 35 countries

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Will Nifty scale new highs soon? Analyst decodes with three stock picks

Stocks to buy: Ajit Mishra of Religare Broking recommends buying Bank of Baroda, Coforge, and Sun Pharma; also suggests Nifty trading strategy

AstraZeneca, Sun Pharma sign deal to distribute hyperkalaemia drug in India

AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands

Innovative portfolio likely to maintain growth momentum for Sun Pharma

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxcyt to anchor next phase

Sun Pharma Q2 net profit rises 2.5% to ₹3,118 crore on India, EM growth

Sun Pharma's Q2FY26 profit rose to Rs 3,118 crore as India, emerging markets, and rest of world drove growth; US revenues fell 4.1% despite strong gains in innovative medicines

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period